Autopsy report · NCT03983668

CMP-001 for Relapsed and Refractory Lymphoma

“Manufacturing issue with investigational drug”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 5 years 2 months before it stopped.
• 14 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Umar Farooq

Sponsor type

University, hospital or other

Conditions

Lymphoma

Interventions

CMP-001; Pembrolizumab

Participants

14

Sites

1

Countries

United States

Trials that died the same way

• Low-dose Gonal-f® in Ovulation Induction
  “Study was terminated because of delays in sourcing replacement Investigational Medicinal Product for the study due to manufacturing delays.” (63% match in meaning)
• P1101 in Treating Patients With Myelofibrosis
  “Study drug became commercially available” (62% match in meaning)
• 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
  “Pharmaceutical Company withdrew support and investigational product” (61% match in meaning)
• tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr
  “Unexpected toxicity events were documented during interim safety evaluations of the investigational drug.” (57% match in meaning)
• Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer
  “Drug sponsor stopped drug manufacture due to toxicity issues from other studies” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.